# Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke

> **NCT07003386** · PHASE2,PHASE3 · RECRUITING · sponsor: **Shanghai Yueyang Integrated Medicine Hospital** · enrollment: 66 (estimated)

## Conditions studied

- Acute Ischemic Stroke AIS

## Interventions

- **DRUG:** Galantamine
- **DRUG:** Standard treatment for acute ischemic stroke

## Key facts

- **NCT ID:** NCT07003386
- **Lead sponsor:** Shanghai Yueyang Integrated Medicine Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2028-09-14
- **Final completion:** 2028-09-30
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07003386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07003386, "Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating Ischemic Stroke". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07003386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*